drugset / Trial / NCT06232655
Cladribine Venetoclax in Monocytic AML
Phase 2
Recruiting
20 enrolled
University of Colorado, Denver
The Leukemia and Lymphoma Society · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
Timeline
- Start
- 2024-02-08
- Primary completion
- 2026-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Cladribine | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |